• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives

    Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations.

    Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare sector. His career began on Wall Street as a stockbroker, transitioning into investment banking roles at various firms in New York City. He co-founded Creation Capital LLC and Creation Capital Advisors, investment banking firms with offices in New York and Austin, Texas, focusing on founding and funding breakthrough healthcare technologies.

    Throughout his career, Mr. Honigblum has raised over half a billion dollars for various ventures. Notably, Mr. Honigblum was instrumental in providing early-stage capital for Myriad Genetics, the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and was subsequently acquired by Merck for $620 million.

    "Gregg's appointment as Chief Strategy Officer reflects our confidence in his ability to elevate SINTX's financial and strategic position," said Eric K. Olson, CEO of SINTX Technologies. "His successful career in emerging technologies and deep investment banking knowledge will be invaluable as we pursue new development opportunities, strengthen investor relationships, and drive our corporate strategy and revenue forward."

    Mr. Honigblum's deep understanding of the Company's mission and strategic goals, coupled with his experience as a former member of the board of Amedica, the predecessor of SINTX, positions him to drive the Company's corporate strategy effectively.

    "I am honored to join SINTX at this pivotal juncture," said Gregg R. Honigblum, Chief Strategy Officer. "The Company's ongoing development of pioneering technologies in the medical device sector positions it at the forefront of commercialization. I look forward to contributing to the team's efforts in enhancing shareholder value and drive the Company's vision forward."

    For more information, please visit www.sintx.com

    About SINTX Technologies, Inc.

    SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. The Company has manufacturing and R&D facilities in Utah and Maryland. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding advancement of ceramic technologies and exploring new avenues for growth and innovation, and the potential to pursue growth opportunities and explore strategic opportunities.

    Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.

    Business and Media Inquiries for SINTX:

    SINTX Technologies

    801.839.3502

    [email protected]



    Primary Logo

    Get the next $SINT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition

    Company Reinforces Commercialization Focus and Strategic Direction SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with the filing of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission and available at www.sec.gov. The business update highlights meaningful progress from the Company's recent SiNAPTIC acquisition, decisive strategic transformation, and a revitalized commercialization strategy

    8/15/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates

    SALT LAKE CITY, Utah, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for musculoskeletal applications, today announced the publication of a peer-reviewed study in the Journal of the Mechanical Behavior of Biomedical Materials. The study validates the use of silicon nitride (Si₃N₄) surface coatings on carbon fiber–reinforced polyetherketoneketone (CFR-PEKK) trauma plates—marking a significant expansion of SINTX's biomaterial platform into additively-manufactured polymer-carbon-ceramic constructs. The research, supported by the National Institute of Arthritis and Musc

    8/4/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices

    Advanced Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market SALT LAKE CITY, Utah, July 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical applications, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its novel silicon nitride osteotomy wedges—marking the official entry into the foot and ankle reconstruction market. These next-generation implants blend cutting-edge biomaterials science with surgical precision and are designed to

    7/22/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $10,756 worth of shares (3,000 units at $3.59) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $185,000 worth of shares (50,000 units at $3.70), increasing direct ownership by 357% to 64,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    President and CEO Olson Eric K. bought $37,470 worth of shares (10,475 units at $3.58), increasing direct ownership by 72% to 24,975 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/25/25 5:14:09 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $10,756 worth of shares (3,000 units at $3.59) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $185,000 worth of shares (50,000 units at $3.70), increasing direct ownership by 357% to 64,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    President and CEO Olson Eric K. bought $37,470 worth of shares (10,475 units at $3.58), increasing direct ownership by 72% to 24,975 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/25/25 5:14:09 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    SEC Filings

    View All

    SEC Form 10-Q filed by SiNtx Technologies Inc.

    10-Q - Sintx Technologies, Inc. (0001269026) (Filer)

    8/14/25 4:16:35 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by SiNtx Technologies Inc.

    DEF 14A - Sintx Technologies, Inc. (0001269026) (Filer)

    7/31/25 5:00:32 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    7/22/25 7:15:22 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Financials

    Live finance-specific insights

    View All

    SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

    Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

    6/24/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

    The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

    7/6/22 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Issues 2022 10-K and Announces Investor Conference Call

    SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced today the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission. In 2021, SINTX made significant investments into the expansion of its three priority business segments - biomedical, industrial/armor, and antipathogenic - through the purchase of new technology, equipment, and personnel. The Company is narrowly focused on opportunities closest to revenue such as armor materials and plates, the development of new biomedi

    3/25/22 5:41:39 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SiNtx Technologies Inc.

    SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

    4/1/24 4:17:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    2/13/24 8:12:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care